PD-1 inhibition in sarcoma still needs investigation - Authors' reply.

Tawbi, Hussein A; Bolejack, Vanessa; Burgess, Melissa; Schuetze, Scott

Tawbi, Hussein A; Bolejack, Vanessa; Burgess, Melissa; Schuetze, Scott.

Afiliación

Tawbi HA; Department of Melanoma Medical Oncology and Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: sarc028@sarctrials.org.
Bolejack V; Cancer Research and Biostatistics, Seattle, WA, USA.
Burgess M; Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Schuetze S; Department of Medicine, University of Michigan, Ann Arbor, MI, USA.

Lancet Oncol ; 19(1): e7, 2018 01.

Article en En | MEDLINE | ID: mdl-29304367

Asunto(s)

Receptor de Muerte Celular Programada 1; Sarcoma; Humanos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Sarcoma / Receptor de Muerte Celular Programada 1 Límite: Humans Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2018 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google